Differential effects of a gelatinase inhibitor on adipocyte differentiation and adipose tissue development

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 10, 2013, Pages 689-697

  Van Hul, Matthias ^a   Bauters, Dries ^a   Lijnen, Roger H ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adipocyte; Adipogenesis; Adipose tissue; Gelatinase; Matrix metalloproteinase; Matrix metalloproteinase inhibitor; Obesity

Indexed keywords

ADIPONECTIN; BETA ACTIN; FATTY ACID; FATTY ACID TRANSPORTER; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOLYLSAM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HOUSEKEEPING GENE; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID OXIDATION; LIPID STORAGE; MALE; METABOLIC RATE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PROADIPOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; GELATINASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; OBESITY;

3T3 CELLS; ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; GELATINASES; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MICE, NUDE; OXADIAZOLES; SULFONAMIDES; TRIGLYCERIDES;

EID: 84884683556     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12154     Document Type: Article

References (39)

1. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J. Obes. 2011; 2011: 179674.
2. Lee SS, Pineau T, Drago J et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995; 15: 3012-22.
3. Bauters D, Van Hul M, Lijnen HR. Macrophage elastase (MMP-12) in expanding murine adipose tissue. Biochim. Biophys. Acta 2013; 1830: 2954-9.
4. Lijnen HR, Maquoi E, Demeulemeester D, Van Hoef B, Collen D. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb. Haemost. 2002; 88: 345-53.
5. Maquoi E, Demeulemeester D, Voros G, Collen D, Lijnen HR. Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation. Thromb. Haemost. 2003; 89: 696-704.
6. Pendas AM, Folgueras AR, Llano E et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell. Biol. 2004; 24: 5304-13.
7. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 2006; 125: 577-91.
8. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J. Thromb. Haemost. 2008; 6: 1198-206.
9. Van Hul M, Piccard H, Lijnen HR. Gelatinase B (MMP-9) deficiency does not affect murine adipose tissue development. Thromb. Haemost. 2010; 104: 165-71.
10. Lijnen HR, Van Hoef B, Rodriguez JA, Paramo JA. Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity. Biochem. Biophys. Res. Commun. 2009; 389: 378-81.
11. Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: Involvement in adipose differentiation. Diabetes 2001; 50: 2080-6.
12. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093-101.
13. Chavey C, Mari B, Monthouel MN et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem. 2003; 278: 11888-96.
14. Bourlier V, Zakaroff-Girard A, De Barros S et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J. Pharmacol. Exp. Ther. 2005; 312: 1272-9.
15. Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb. Haemost. 2003; 89: 249-55.
16. Stradecki HM, Jaworski DM. Hyperphagia and leptin resistance in tissue inhibitor of metalloproteinase-2 deficient mice. J. Neuroendocrinol. 2011; 23: 269-81.
17. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 1999; 96: 7473-8.
18. Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke 2007; 38: 162-9.
19. Van Hul M, Bauters D, Himmelreich U et al. Effect of gelatinase inhibition on adipogenesis and adipose tissue development. Clin. Exp. Pharmacol. Physiol. 2012; 39: 49-56.
20. Lijnen HR, Christiaens V, Scroyen I et al. Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes 2006; 55: 2698-704.
21. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington DC. 1996.
22. Giles AR. Guidelines for the use of animals in biomedical research. Thromb. Haemost. 1987; 58: 1078-84.
23. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res. Cardiol. 1994; 89: 397-410.
24. Aoyama T, Peters JM, Iritani N et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998; 273: 5678-84.
25. Fan CY, Pan J, Chu R et al. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J. Biol. Chem. 1996; 271: 24698-710.
26. Mandrup S, Loftus TM, MacDougald OA, Kuhajda FP, Lane MD. Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3-F442A preadipocytes. Proc. Natl Acad. Sci. USA 1997; 94: 4300-5.
27. Neels JG, Thinnes T, Loskutoff DJ. Angiogenesis in an in vivo model of adipose tissue development. FASEB J. 2004; 18: 983-5.
28. Scroyen I, Cosemans L, Lijnen HR. Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation. Thromb. Res. 2009; 124: 578-83.
29. Van Hul M, Lupu F, Dresselaers T, Buyse J, Lijnen HR. Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice. Clin. Exp. Pharmacol. Physiol. 2012; 39: 544-50.
30. Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 374-9.
31. Croissandeau G, Chretien M, Mbikay M. Involvement of matrix metalloproteinases in the adipose conversion of 3T3-L1 preadipocytes. Biochem. J. 2002; 364: 739-46.
32. Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution. J. Cell Biol. 2001; 152: 693-703.
33. Van Hul M, Lijnen HR. Matrix metalloproteinase inhibition impairs murine adipose tissue development independently of leptin. Endocr. J. 2011; 58: 101-7.
34. Lee MH, Atkinson S, Murphy G. Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J. Biol. Chem. 2007; 282: 6887-98.
35. Lambert V, Wielockx B, Munaut C et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003; 17: 2290-2.
36. Masson V, de la Ballina LR, Munaut C et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005; 19: 234-6.
37. Silvestri E, Schiavo L, Lombardi A, Goglia F. Thyroid hormones as molecular determinants of thermogenesis. Acta Physiol. Scand. 2005; 184: 265-83.
38. Cioffi F, Lanni A, Goglia F. Thyroid hormones, mitochondrial bioenergetics and lipid handling. Curr. Opin. Endocrinol. Diabetes Obes. 2010; 17: 402-7.
39. Calvo RM, Obregon MJ. Presence and regulation of D1 and D2 deiodinases in rat white adipose tissue. Metabolism 2011; 60: 1207-10.